rofecoxib has been researched along with Disease Exacerbation in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 9.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 5.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| "Six patients with advanced and pretreated but progressive, malignant vascular tumors (5 angiosarcomas and 1 hemangioendothelioma) received a combination of pioglitazone (45 mg per day orally) plus rofecoxib (25 mg per day orally) and, after 14 days, trofosfamide (3 x 50 mg per day orally)." | 5.10 | Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. ( Andreesen, R; Bataille, F; Berand, A; Bross, K; Hafner, C; Jauch, KW; Landthaler, M; Reichle, A; Vogt, T, 2003) |
| " At this time, celecoxib is the only available COX-2-specific inhibitor for treatment of pain and inflammation." | 3.85 | COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages. ( Carsons, SE; De Leon, J; Gomolin, IH; Kasselman, LJ; Littlefield, MJ; Reiss, AB; Voloshyna, I, 2017) |
| "Patients with Crohn's disease, ulcerative colitis, or pouchitis who used celecoxib or rofecoxib were identified from computerized prescription records." | 3.71 | Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. ( Loftus, EV; Mahadevan, U; Sandborn, WJ; Tremaine, WJ, 2002) |
| "Gefitinib 250 mg/d was combined with rofecoxib (dose escalated from 12." | 2.73 | Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. ( Botwood, N; Carbone, D; Danson, S; Dunlop, D; O'Byrne, KJ; Ranson, M; Taguchi, F, 2007) |
| "Diagnostic delay and misdiagnoses of unilateral headaches, as illustrated by this case, shows the clinical controversies and difficulties in diagnosing and treating this condition." | 1.37 | [A woman with unilateral headache]. ( Bekkelund, SI; Müller, KI, 2011) |
| " As prostaglandin E2 levels in spinal cord or in plasma were not reduced by Rofecoxib treatment, these results may suggest lack of sufficient bioavailability as the reason for the modest clinical changes observed." | 1.33 | Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS. ( Azari, MF; Cheema, SS; Hirst, J; Le Grande, MR; Lopes, EC; Petratos, S; Profyris, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (73.91) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grabosch, SM | 2 |
| Shariff, OM | 2 |
| Helm, CW | 2 |
| Wulff, JL | 1 |
| Ungprasert, P | 1 |
| Srivali, N | 1 |
| Kittanamongkolchai, W | 1 |
| Voloshyna, I | 1 |
| Kasselman, LJ | 1 |
| Carsons, SE | 1 |
| Littlefield, MJ | 1 |
| Gomolin, IH | 1 |
| De Leon, J | 1 |
| Reiss, AB | 1 |
| Walter, B | 1 |
| Rogenhofer, S | 1 |
| Vogelhuber, M | 1 |
| Berand, A | 2 |
| Wieland, WF | 1 |
| Andreesen, R | 2 |
| Reichle, A | 2 |
| Müller, KI | 1 |
| Bekkelund, SI | 1 |
| Aisen, PS | 2 |
| Schafer, KA | 1 |
| Grundman, M | 1 |
| Pfeiffer, E | 1 |
| Sano, M | 1 |
| Davis, KL | 1 |
| Farlow, MR | 1 |
| Jin, S | 1 |
| Thomas, RG | 1 |
| Thal, LJ | 3 |
| Candelario-Jalil, E | 1 |
| González-Falcón, A | 1 |
| García-Cabrera, M | 1 |
| Alvarez, D | 1 |
| Al-Dalain, S | 1 |
| Martínez, G | 1 |
| León, OS | 1 |
| Springer, JE | 1 |
| Spieth, K | 1 |
| Kaufmann, R | 1 |
| Gille, J | 1 |
| Czap, A | 1 |
| Higuchi, T | 1 |
| Iwama, T | 1 |
| Yoshinaga, K | 1 |
| Toyooka, M | 1 |
| Taketo, MM | 1 |
| Sugihara, K | 1 |
| Vogt, T | 1 |
| Hafner, C | 1 |
| Bross, K | 1 |
| Bataille, F | 1 |
| Jauch, KW | 1 |
| Landthaler, M | 1 |
| Reines, SA | 2 |
| Block, GA | 2 |
| Morris, JC | 1 |
| Liu, G | 1 |
| Nessly, ML | 3 |
| Lines, CR | 3 |
| Norman, BA | 3 |
| Baranak, CC | 2 |
| Krum, H | 1 |
| Liew, D | 1 |
| Aw, J | 1 |
| Haas, S | 1 |
| Peluffo, GD | 1 |
| Stillitani, I | 1 |
| Rodríguez, VA | 1 |
| Diament, MJ | 1 |
| Klein, SM | 1 |
| Aizen, E | 1 |
| Kagan, G | 1 |
| Assy, B | 1 |
| Iobel, R | 1 |
| Bershadsky, Y | 1 |
| Gilhar, A | 1 |
| Ferris, SH | 2 |
| Kirby, L | 1 |
| Yuen, E | 1 |
| Assaid, C | 2 |
| Azari, MF | 1 |
| Profyris, C | 1 |
| Le Grande, MR | 1 |
| Lopes, EC | 1 |
| Hirst, J | 1 |
| Petratos, S | 1 |
| Cheema, SS | 1 |
| Ownby, RL | 1 |
| Treiber, G | 1 |
| Wex, T | 1 |
| Röcken, C | 1 |
| Fostitsch, P | 1 |
| Malfertheiner, P | 1 |
| O'Byrne, KJ | 1 |
| Danson, S | 1 |
| Dunlop, D | 1 |
| Botwood, N | 1 |
| Taguchi, F | 1 |
| Carbone, D | 1 |
| Ranson, M | 1 |
| Giuliani, MJ | 1 |
| Potter, WZ | 1 |
| Mahadevan, U | 1 |
| Loftus, EV | 1 |
| Tremaine, WJ | 1 |
| Sandborn, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease[NCT00004845] | Phase 2/Phase 3 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for rofecoxib and Disease Exacerbation
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 In | 2018 |
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitor | 2014 |
Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Progression; Heart Failure; Humans; Lact | 2015 |
Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Topics: Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Celecoxib; Clinical Trials as To | 2004 |
12 trials available for rofecoxib and Disease Exacerbation
| Article | Year |
|---|---|
Modular therapy approach in metastatic castration-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamet | 2010 |
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cycloo | 2003 |
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Cell Division; Cell Survival; C | 2003 |
A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Topics: Adenomatous Polyposis Coli; Adult; Colonic Polyps; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2003 |
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Pro | 2003 |
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein E4; Apolipoproteins | 2004 |
Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cerebral | 2005 |
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Topics: Aged; Cognition Disorders; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2005 |
Rofecoxib in mild cognitive impairment.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Disea | 2006 |
Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2006 |
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2007 |
Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cognition Disorders; Cyclooxygenase 2 In | 2008 |
7 other studies available for rofecoxib and Disease Exacerbation
| Article | Year |
|---|---|
COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biological Transport; Celecoxib; Cell Adhe | 2017 |
[A woman with unilateral headache].
Topics: Chronic Disease; Cyclooxygenase 2 Inhibitors; Delayed Diagnosis; Diagnosis, Differential; Disease Pr | 2011 |
Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia.
Topics: Animals; Antioxidants; Biomarkers; Cell Count; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 | 2003 |
Pass the tablet please.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Ginkgo biloba | 2003 |
Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cell Survival; Chem | 2004 |
Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Blotting, Western; Cyclooxygenase Inhibitors; Dinoprostone; | 2005 |
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
Topics: Adult; Aged; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2002 |